Article quick-view

Open access? Widening access to Chimeric Antigen Receptor (CAR) therapy for ALL.


T cells that are genetically modified to express chimeric antigen receptors (CARs) specific for CD19 show great promise for the treatment of relapsed/refractory acute lymphoblastic leukaemia (ALL). The first FDA approval of a cellular cancer therapy in 2017, i.e. Novartis' CD19-targeting CAR T cell product Kymriah™ within the context of relapsed/refractory paediatric ALL, followed rapidly by approval of Kite's Yescarta™ and more recently, Kymriah™ for diffuse large B cell indications in adults, highlighted the pace of progress made in this field. In this review, we will consider the latest evidence from CAR T cell therapy for B lineage acute lymphoblastic leukaemia. We discuss the barriers to CAR T cell therapy for ALL patients and give a perspective on the strategy we have taken to date to widen access to CAR T cell therapy for UK paediatric patients with high risk ALL. Copyright © 2018. Published by Elsevier Inc.